Long Non-Coding RNAs in Pathogenesis of Renal Cell Carcinoma: Epigenetic Regulation, Signaling Pathways, and Therapeutic Strategies
Open Access
- 3 June 2026
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (11) , 5071
Abstract
Renal cell carcinoma (RCC) remains a major challenge in modern oncological urology, owing to its high heterogeneity, latent clinical course, and intrinsic resistance to chemotherapy and radiotherapy. In recent decades, the paradigm of carcinogenesis research has shifted from a primary focus on protein-coding genes alone to a broader investigation of the non-coding part of the transcriptome. Within this framework, long non-coding RNAs (lncRNAs) have emerged as fundamental regulators of cellular homeostasis. Accumulating evidence indicates that lncRNAs are not merely ‘transcriptional noise’ but components of intricate regulatory networks governing epigenetic, transcriptional, and post-transcriptional processes. Here, we present a comprehensive systematic review of the current literature addressing the role of lncRNA in the molecular pathogenesis of RCC. We discuss the roles of these molecules in key oncogenic signaling pathways, including PI3K/AKT/mTOR, Wnt/β-catenin, and Notch, and their contributions to tumor metabolic plasticity. The paper summarizes data on the link between lncRNAs and novel forms of regulated cell death—ferroptosis, cuproptosis, and disulphidosis. Particular attention is paid to their role in mediating resistance to tyrosine kinase inhibitors and their potential utility as highly specific biomarkers. Collectively, this review provides an updated perspective on the contribution of lncRNAs to RCC pathogenesis and outlines strategic directions for future research to support the development of more precise approaches in personalized oncology.Keywords
Funding Information
- Bashkir State Medical University (PRIORITY-2030)
This publication has 149 references indexed in Scilit:
- Long Noncoding RNA E2F1 Messenger RNA Stabilizing Factor (EMS) Promotes Sorafenib Resistance in Renal Cell Carcinoma by Regulating miR‐363‐3p and Dual‐Specificity Phosphatase 10 ExpressionJournal of Biochemical and Molecular Toxicology, 2025
- FOXD2‐AS1 Binding to MYC Activates EGLN3 to Affect the Malignant Progression of Clear Cell Renal Cell CarcinomaJournal of Biochemical and Molecular Toxicology, 2024
- Ursolic acid‐downregulated long noncoding RNA ASMTL‐AS1 inhibits renal cell carcinoma growth via binding to HuR and reducing vascular endothelial growth factor expressionJournal of Biochemical and Molecular Toxicology, 2023
- RP11‐367G18.1 V2 enhances clear cell renal cell carcinoma progression via induction of epithelial–mesenchymal transitionCancer Medicine, 2023
- LncRNA GABPB1‑IT1 inhibits the tumorigenesis of renal cancer via the miR‐21/PTEN axisJournal of Biochemical and Molecular Toxicology, 2023
- Long noncoding RNA‐LINC00478 promotes the progression of clear cell renal cell carcinoma through PBX3Journal of Biochemical and Molecular Toxicology, 2022
- LncRNA SNHG1 promotes renal cell carcinoma progression through regulation of HMGA2 via sponging miR‐103aJournal of Clinical Laboratory Analysis, 2022
- New insights into the interplay between long non‐coding RNAs and RNA‐binding proteins in cancerCancer Communications, 2022
- LncRNA SNHG1 regulates immune escape of renal cell carcinoma by targeting miR‐129‐3p to activate STAT3 and PD‐L1Cell Biology International, 2021
- lncRNA MSC‐AS1 activates Wnt/β‐catenin signaling pathway to modulate cell proliferation and migration in kidney renal clear cell carcinoma via miR‐3924/WNT5AJournal of Cellular Biochemistry, 2020